Health Care & Life Sciences » Pharmaceuticals | Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Ltd. | Balance Sheet

Fiscal year is January-December. All values HKD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
60,523.50
87,768.30
71,856.20
296,187.20
90,814.90
91,619.70
Total Accounts Receivable
47,784.80
127,486.30
116,739.20
64,930.30
116,117.90
29,851.10
Inventories
239,409.60
140,421.00
56,357.30
177,080.20
353,316.30
244,955.60
Other Current Assets
2,183.70
4,432.40
11,968.50
8,545.80
100,755.80
73,848.40
Total Current Assets
349,901.80
360,108.00
256,921.20
546,743.50
661,004.80
440,274.80
Net Property, Plant & Equipment
132,756.00
191,398.80
202,119.00
227,111.10
270,791.70
242,460.50
Intangible Assets
-
-
90,591.90
101,619.30
28,719.50
128.90
Other Assets
-
-
4,412.40
3,346.90
11,916.80
13,280.60
Total Assets
482,657.80
551,506.80
554,044.50
878,820.90
983,427.60
697,627.20
ST Debt & Current Portion LT Debt
65,979.70
114,732.80
97,766.00
184,080.80
491,787.60
Accounts Payable
9,664.80
23,295.80
74,943.80
51,132.10
27,036.40
Income Tax Payable
9,365.10
6,974.90
10,632.90
13,634.30
3,056.30
Other Current Liabilities
335,714.50
252,150.10
139,693.90
119,818.80
134,149.80
Total Current Liabilities
420,724.10
397,153.60
323,036.70
368,665.90
656,030.20
Deferred Taxes
-
-
-
-
10,994.90
Total Liabilities
420,724.10
397,153.60
323,036.70
368,665.90
656,030.20
Common Equity (Total)
52,316.30
131,515.00
230,857.50
511,163.50
328,483.90
Total Shareholders' Equity
52,316.30
131,515.00
230,857.50
511,163.50
328,483.90
Total Equity
61,933.70
154,353.30
231,007.80
510,154.90
327,397.50
Liabilities & Shareholders' Equity
482,657.80
551,506.80
554,044.50
878,820.90
983,427.60
Accumulated Minority Interest
9,617.40
22,838.30
150.40
1,008.50
1,086.40

About Sinco Pharmaceuticals Holdings

View Profile
Address
E5-1805, Global Centre
Chengdu Sichuan 610041
China
Employees -
Website http://www.sinco-pharm.com
Updated 07/08/2019
Sinco Pharmaceuticals Holdings Ltd. engages in the marketing, promotion, and channel management services for pharmaceutical products and medical devices. It improves human plasma-based pharmaceutical, antibiotics, and other pharmaceuticals focused on therapeutic areas complementary to human plasma-based products. It offers human albumin solution, Axetine, Medocef, and Trifamox IBL.